

August 7, 2019

The General Manager
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400 001

The Manager
National Stock Exchange of India Limited
Listing Department
Exchange Plaza
5th Floor, Plot No. C-1, Block-G
Bandra-Kurla Complex, Bandra(E)
Mumbai-400 051

BSE Scrip Code: 532281

NSE Scrip Code: HCLTECH

Sub.: HCL Technologies appoints Dr. Mohan Chellappa on its Board

Dear Sir,

We would like to inform you that Dr. Mohan Chellappa has been appointed as an Additional Director on the Board of the Company w.e.f. August 6, 2019 to hold office as an Independent Director.

He shall hold office as an Independent Director for a period of 5 years subject to the approval of the shareholders at the next Annual General Meeting of the Company. He is not related to any of the Directors of the Company.

Dr. Chellappa is not debarred from holding office of director by virtue of any SEBI Order or any other authority.

A Release in this regard is enclosed.

This is for your information and records.

Thanking you,

Yours faithfully,
For **HCL Technologies Limited**



Manish Anand
Company Secretary

Encl: a/a

HCL Technologies appoints Dr. Mohan Chellappa to the Board of Directors

NOIDA, India- August 7, 2019- HCL Technologies (HCL), a leading global technology company, today announced the appointment of Dr. Mohan Chellappa, M.D., as an Independent Director on its Board. With the addition of Dr. Chellappa, the Board strength of the company increases to 11 Directors, including nine Independent Directors and three women Directors. Dr. Chellappa's appointment is effective August 6, 2019.

Welcoming Dr. Chellappa to the Board, Shiv Nadar, Chairman and Chief Strategy Officer, HCL Technologies said, "I am delighted to welcome Dr. Chellappa to the Board of HCL. His rich experience will certainly help the Company continue its journey towards growth and excellence. We appreciate Dr. Chellappa's decision to become a part of HCL Technologies and look forward to working with him."

Dr. Chellappa currently serves as the President, Global Ventures, of Johns Hopkins Medicine International (JHMI). A founding member of JHMI, he is involved in the development of international clinical consultancy activities, in clinical care program development, quality systems implementation and utilization of IT in healthcare. Dr. Chellappa has been instrumental in securing and establishing several engagements of Johns Hopkins Medicine globally, including the establishment of Johns Hopkins Aramco Healthcare, a joint venture with Aramco, the world's largest energy company.

He serves on the boards of HCL Healthcare and Johns Hopkins Aramco Healthcare. He has a special interest in the effectiveness of corporate boards and completed a program in that area at Harvard Business School.

Commenting on his appointment, Dr. Chellappa said, "I am extremely honored and delighted that the Board of HCL Technologies has decided to make me a part of one of the world's leading technology companies. I look forward to being a part of the success story of HCL."

A surgeon by profession, Dr. Chellappa is a Fellow of the Royal College of Surgeons of Edinburgh and a Fellow of the American College of Surgeons. Dr. Chellappa, who also holds a business degree, has wide surgical experience, having worked in countries such as India, Malaysia, Singapore, the UK and the USA. He underwent special training in surgical gastroenterology at the University of Leeds and Hammersmith Hospital in 1982 and in liver and kidney transplantation at the University of Louvain in Brussels in 1986. He is an avid follower of technology and has been part of the Artificial Intelligence consortium for Healthcare in gulf council country.

About HCL Technologies

HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL's Mode 1-2-3 strategy through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses transform into next-gen enterprises.

HCL offers its services and products through three business units: IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences & Healthcare and Public Services.





As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability and education initiatives. As of 12 months ended June 30, 2019, HCL has a consolidated revenue of US\$ 8.9 billion and its 143,900 ideapreneurs operate out of 44 countries.

For more information, visit www.hcltech.com

Forward-looking Statements

Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to the statements containing the words 'planned', 'expects', 'believes', 'strategy', 'opportunity', 'anticipates', 'hopes' or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, business process outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost-effective and timely manner, time and cost overruns on fixed-price, fixed-timeframe contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies /entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward-looking statements made herein will prove to be accurate, and issuance of such forward-looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward-looking statements made herein are based on information presently available to the Management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.

For further details, please contact:
HCL Technologies

Ravi Kathuria
Ravi.Kathuria@hcl.com

